Cardiovascular disease is the leading cause of death in women. Women’s heart disease risk tends to lag about 10 years behind that of men; thus, at any given age, a woman’s baseline risk will be lower than that of a man’s baseline risk. While some heart disease risk factors such as age and family history are not modifiable, other risk factors such as hypertension, hyperlipidemia, smoking, obesity, and diabetes are potentially modifiable. Additionally, sex-specific risk factors may impact a woman’s risk of future heart disease, including adverse pregnancy outcomes (ie, preeclampsia, gestational diabetes, preterm birth, or small for gestational age birth), premature ovarian failure or early menopause, or comorbidities such as autoimmune disease or the sequelae of cancer treatments (ie, chest wall radiation, or trastuzumab or anthracycline treatment for breast cancer). Each of these may be considered a “risk-enhancer” when considering future cardiovascular disease risk.
Decision making about preventive treatment is affected by overall cardiovascular risk. The Framingham risk calculator (http://cvdrisk.nhlbi.nih.gov/) can be used to estimate a woman’s 10-year risk of coronary heart disease (CHD) based on her age, smoking status, blood pressure, and cholesterol levels. In addition to the risk factors in the Framingham risk calculator, the pooled cohort equations to predict 10-year risk of atherosclerotic cardiovascular disease (ASCVD) includes self-identified race (White or other vs African American) and diabetes (http://clincalc.com/Cardiology/ASCVD/PooledCohort.aspx). The 2018 AHA/American College of Cardiology Multisociety cholesterol guideline encourages clinicians to elicit a history of risk-enhancers specific to women and consider elevating a patient to a higher risk category when one or more are present.
Beyond treatment of risk factors such as hypertension, diabetes, and hyperlipidemia, decision making about whether to take aspirin for cardiovascular disease prevention is important. Some studies have suggested that aspirin may be helpful for primary prevention of stroke in women but not for primary CHD prevention. Recent studies, however, suggest that aspirin may not reduce all-cause mortality when used for primary prevention for those with moderate risk of atherosclerotic disease, including the healthy elderly. Current guidelines regarding aspirin for primary prevention of cardiovascular disease are not gender specific and focus on balancing the overall risk of cardiovascular disease against the risk of bleeding. Cardiovascular disease, risk factors, and therapeutic options for risk factor reduction and prevention are discussed in Chapter 1-04.
et al. The use of sex-specific factors in the assessment of women’s cardiovascular risk. Circulation. 2020;141:592.
ASCEND Study Collaborative Group; Bowman
et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529.
et al. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:836.
et al; ARRIVE Executive Committee. Use of aspirin to reduce ...